Evidence map›Paper›PMID 33820772›Full record

ArticleAntimicrobial agents and chemotherapy2021

Trends of Antimicrobial Resistance and Combination Susceptibility Testing of Multidrug-Resistant Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients: a 10-Year Update.

Ijeoma N Okoliegbe, Karolin Hijazi, Kim Cooper, Corinne Ironside, Ian M Gould

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Antibacterial peptide Reg4 amelioratesMicrobiology spectrum · 2024
    Article
  6. mBio · 2024
    Article
  7. Article
  8. Article
  9. Frontiers in medicine · 2023
    Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ijeoma N OkoliegbeDepartment of Medical Microbiology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom ijeoma.okoliegbe@nhs.scot.ORCID 0000-0002-7886-7064
Karolin HijaziInstitute of Dentistry, University of Aberdeen, Aberdeen, United Kingdom.ORCID 0000-0002-8589-2129
Kim CooperDepartment of Medical Microbiology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom.
Corinne IronsideDepartment of Medical Microbiology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom.
Ian M GouldDepartment of Medical Microbiology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom.
Aberdeen Royal Infirmary · GBUniversity of Aberdeen · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial combination therapy is a time/resource-intensive procedure commonly employed in the treatment of cystic fibrosis (CF) pulmonary exacerbations caused by

Indexed as

Cystic FibrosisPseudomonas InfectionsAnti-Bacterial AgentsCeftazidimeCephalosporinsDrug Resistance, BacterialDrug Resistance, Multiple, BacterialHumansMicrobial Sensitivity TestsPseudomonas aeruginosaAnti-Bacterial AgentsCeftazidimeCephalosporinsantimicrobial susceptibility testingcystic fibrosisEtestPseudomonas aeruginosasynergy testing

Identifiers

PMID33820772
PMCPMC8316036
OpenAlexW3150381630

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.